Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People with Overweight and Obesity.

Expiry Date
: 10/05/2024
CPD Units
: 3.00 Points
Rating
: Not yet rated.

This article reviews treatment options used to manage overweight and obesity, focusing on the role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes.

Keywords: GLP-1 receptor agonists, obesity, overweight, weight loss

Reading material:

Educational Objectives

Educational Aim:
Understand the role of glucagon-like peptide-1 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity.

Educational Outcomes:
Upon completion of this module practitioners should have a clear understanding of:

    1. Advantages and disadvantages of the different treatment options available to manage overweight and obesity.  

    1. Advantages and disadvantages of the different treatment options available to manage overweight and obesity. 

    1. Understanding barriers to the treatment of overweight and obesity. 

Instructions for this Module

  • Read the supplied reading material and complete the quiz that follows;
  • You have three attempts to pass the quiz;
  • The pass grade is 70%;
  • You need to pass the quiz to claim your CPD certificate;
  • Please click on the CPD certificate link below to claim your CPD certificate and to update your CPD Manager.

If you need any assistance to complete this module, please Contact us